Mesa Laboratories (MLAB) AI Stock Analysis

• Market Cap: $626.60M
• Dividend Yield: 0.55%
• Average Volume (3M): 42.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: 11.68%
• EPS Growth: -26360.70%
• Country: US
• Employees: 736
• Sector: Technology
• Sector Strength: 76
• Industry: Hardware, Equipment & Parts
• EPS (TTM): -46.25
• Shares Outstanding: 5,433,607
• 10 Day Avg. Volume: 42,678
• 30 Day Avg. Volume: 42,233
• PEG Ratio: 1.69
• Price to Book (P/B): 4.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 15.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $120.00
• Price Target Upside: 7.17% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: ―

Mesa Laboratories' overall stock score reflects its significant financial challenges, including large net losses and declining equity ratio. While positive cash flow generation is a positive, technical analysis indicates bearish momentum. The valuation is further strained by a negative P/E ratio, resulting in a lower score.

Mesa Laboratories Business Overview & Revenue Model

Company Description

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

How the Company Makes Money

Mesa Laboratories generates revenue through the sale of its products and services related to quality assurance and control. The company has multiple revenue streams, including direct product sales, recurring service contracts, and calibration and testing services. Product sales include data loggers and biological indicators, which are widely used in industries that require stringent quality control and regulatory compliance. Additionally, Mesa Laboratories offers calibration and testing services, which provide a recurring revenue stream as customers require ongoing maintenance and verification of their equipment's accuracy. The company's strategic partnerships and acquisitions also play a significant role in expanding its product offerings and customer base, thereby contributing to its overall revenue growth.

Mesa Laboratories Financial Statement Overview

Summary

Mesa Laboratories faces significant profitability challenges despite maintaining a reasonable balance sheet and positive cash flow generation. The large negative net income and declining equity ratio are notable risks, while positive cash flow metrics offer a silver lining. The company needs to address its operational inefficiencies to improve financial health.

Income Statement

Mesa Laboratories has shown inconsistent revenue growth with recent declines in profitability. The TTM gross profit margin is approximately 58.94%, indicating efficient cost management relative to revenue. However, the company's net income is significantly negative, leading to a net profit margin of -104.94% for the TTM period, reflecting substantial losses. EBIT and EBITDA margins are also negative, showing operational challenges.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.82 for the TTM, suggesting a balanced capital structure. However, the equity ratio decreased from 59.56% in 2023 to 35.51% in the TTM, indicating a decline in financial stability. Return on equity is negative due to substantial net losses, highlighting profitability concerns.

Cash Flow

The company exhibits a positive free cash flow trend, with TTM free cash flow increasing by 3.45% from 2023. The operating cash flow to net income ratio is strong, indicating good cash flow generation relative to the reported net losses. However, free cash flow to net income ratio is skewed due to negative income.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
237.75M	216.19M	219.08M	184.34M	133.94M	117.69M
	Gross Profit
140.12M	133.25M	133.69M	109.09M	87.01M	64.93M
	EBIT
18.12M	-272.07M	-30.50M	-20.37M	-5.30M	-4.90M
	EBITDA
-236.31M	-238.38M	36.45M	29.77M	12.36M	8.09M
	Net Income Common Stockholders
-249.44M	-254.25M	930.00K	1.87M	3.27M	1.35M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
30.96M	28.21M	32.91M	49.35M	263.87M	81.38M
	Total Assets
437.15M	446.80M	661.83M	707.37M	600.15M	420.21M
	Total Debt
211.61M	231.30M	170.27M	221.13M	146.70M	141.37M
	Net Debt
180.66M	203.08M	137.36M	171.79M	-117.17M	59.99M
	Total Liabilities
281.93M	301.40M	268.35M	313.57M	193.92M	200.19M
	Stockholders Equity
155.21M	145.39M	393.48M	393.80M	406.23M	220.01M
Cash Flow		Free Cash Flow
43.00M	41.57M	23.44M	34.79M	35.08M	25.06M
	Operating Cash Flow
47.03M	44.13M	27.98M	39.22M	37.07M	26.56M
	Investing Cash Flow
-3.07M	-81.31M	-9.49M	-305.23M	-1.99M	-185.59M
	Financing Cash Flow
-41.25M	32.84M	-33.33M	52.58M	146.23M	231.28M

Mesa Laboratories Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 111.97
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLAB, the sentiment is Negative. The current price of 111.97 is below the 20-day moving average (MA) of 119.39, below the 50-day MA of 118.55, and below the 200-day MA of 126.08, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 39.82 is Neutral, neither overbought nor oversold. The STOCH value of 13.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLAB.

Mesa Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LYTS	72 Outperform	$494.47M	23.06	10.42%	1.21%	17.89%	-23.37%
BELFA	71 Outperform	$940.19M	19.37	11.87%	0.35%	-6.15%	-42.24%
FARO	66 Neutral	$809.42M	―	-0.34%	―	-4.76%	97.93%
VPG	61 Neutral	$351.05M	115.17	0.94%	―	-14.26%	-87.37%
DAKT	61 Neutral	$768.36M	32.01	0.72%	―	-1.51%	-96.07%
Sector *	60 Neutral	$11.56B	10.24	-7.04%	2.94%	7.46%	-10.54%
MLAB	51 Neutral	$626.60M	―	-89.38%	0.55%	11.68%	-26360.70%